Transforming Growth Factor beta1 (TGF beta 1)

A subtype of transforming growth factor beta that is synthesized by a wide variety of cells. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta 1 and TGF-beta1 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor. Defects in the gene that encodes TGF-beta1 are the cause of CAMURATI-ENGELMANN SYNDROME.

Also Known As:

Networked: 4733 relevant articles (143 outcomes, 691 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kim, Seong-Jin: 13 articles (03/2010 - 01/2002)
2.	Lan, Hui Y: 9 articles (03/2010 - 03/2005)
3.	Jakowlew, Sonia B: 9 articles (06/2008 - 05/2002)
4.	Liu, Yong: 8 articles (03/2010 - 01/2003)
5.	Fukuda, Noboru: 8 articles (03/2010 - 11/2002)
6.	Wang, Hao: 7 articles (01/2013 - 04/2005)
7.	Wang, Hua: 7 articles (10/2011 - 06/2003)
8.	Wang, Wei: 7 articles (06/2010 - 11/2003)
9.	Liu, X: 7 articles (03/2010 - 03/2000)
10.	Margetts, Peter J: 7 articles (02/2010 - 08/2002)

Related Diseases

1.	Fibrosis (Cirrhosis) 09/01/2010 - "Short-term blockade of TGF-beta1 function after radiation markedly decreased tissue fibrosis and significantly improved lymphatic function but did not alter LEC apoptosis. " 10/01/2007 - "Significant reduction of fibrosis and TGF-beta1 expression was found in the muscles of the scid/mdx mice. " 06/01/2006 - "Significantly greater fibrosis and TGF-beta1 expression were found in mdx from the 6th week. " 08/01/2002 - "It also improved significantly histological changes of fibrosis and decreased the expression of alpha-SMA and TGF-beta1 in liver of these rats (P<0.05 or P<0.01). " 04/01/1999 - "The neutralization of TGF-beta1 has been beneficial in the reduction of fibrosis. "
2.	Proteinuria 08/01/2011 - "Urinary AGT levels correlated positively with proteinuria, urinary TGF-beta1 levels and diastolic blood pressure, but negatively with the estimated glomerular filtration rate (GFR). " 01/01/2010 - "These results suggest that TJN-331 inhibits proteinuria and histopathological changes in glomeruli via suppression of TGF-beta1 production from inflamed glomeruli." 10/01/2009 - "In vivo, to determine the effects of reduced Smad3 or CD2AP gene dosage on podocyte apoptosis and proteinuria characteristic of TGF-beta1 transgenic mice, we generated TGF-beta1 transgenic mice deficient for Smad3 or heterozygous for CD2AP. " 05/01/2009 - "Moreover, sEng levels, but not TGF-beta1 levels, showed a positive correlation with maximum diastolic and systolic blood pressure (r = 0.57, P < 0.001; and r = 0.33, P < 0.001, respectively) and proteinuria (r = 0.42, P < 0.001). " 04/01/2008 - "It was further observed that in the CRF rats, the treatment with TGF-beta1 antisense, but not scrambled ODN, markedly attenuated the reduction of RBF, GFR, and proteinuria and markedly prevented the increase of the FE Na+ (all P<0.05). "
3.	Neoplasms (Cancer) 07/01/2008 - "When the tumor cells were transfected with a TGF-beta1 antisense expressing vector, a significant reduction occurred in the tumor incidence, as well as the tumor burden. " 11/01/2003 - "A significant increase in the serum level of TGF-beta1 correlated with a significant reduction in the level of circulating DCs in cancer patients that was associated with an increased infiltration of Langerhans cells into colorectal mucosa. " 09/01/2010 - "In this study, we investigated the effects of TGF-beta1 on tumor-mesothelial interaction. " 06/01/2009 - "In the presented study the expression of human HtrA1, HtrA2, HtrA3 and TGF-beta1 genes was examined in 124 endometrial tissue specimens including 88 cancers and 36 normal endometria. " 05/15/2009 - "The presence of membrane-bound TGF-beta1 (mTGF-beta1) has been recently observed in regulatory T cells, but only a few studies have reported the same phenomenon in cancer cells. "
4.	Wounds and Injuries (Trauma) 12/15/1996 - "The extent of wound repair, as evidenced by enhanced tensile strength, can be markedly improved in tissues transfected with TGF-beta1 expression constructs." 01/01/1993 - "Immunocytochemical analysis of tissue sections of the wound demonstrated a rapid induction of TGF beta 1 protein within 1 hour post-wounding, but also a subsequent rapid clearance of the protein from the wound site such that, by 18 hours post-wounding, TGF beta 1 levels had returned to near background. " 01/01/1991 - "The single application of TGF-beta 1 improved the healing of open wounds. " 04/01/2008 - "Based on the results on the parameters evaluated in the study, experimental SCI in rats results in delay in wound healing and low intensity of TGF-beta1 in the dorsal wound-tissue specimens." 06/01/2007 - "This study demonstrates that rapid midgestational wound closure in a murine model is associated with increased TGF-beta1 and TbetaR-2 expression. "
5.	Inflammation 01/15/2004 - "Together, these studies demonstrate that TGF-beta1 produced by CD4+CD25+ T cells is involved in the suppressor activity of these cells, particularly in their ability to regulate intestinal inflammation." 01/01/2012 - "One of the members of this pathway, TGF-beta 1, has an important role in controlling gut inflammation in relation to the continuous stimulation of the intestinal microbiota. " 06/01/2011 - "Compared with the control group, the degree of the airway inflammation and hyperresponsiveness and the concentrations of IL-4/IFN-gamma, TGF-beta1 in all four OVA groups increased significantly. " 05/01/2010 - "Malignant derivatives did not induce COX-2 in response to TGF-beta 1 treatment, thus emphasizing the role of inflammation in EMT response of benign cells. " 03/01/2010 - "There was a significant negative correlation between the severity of inflammation and gastric mucosal TGF-beta1 levels. "

Related Drugs and Biologics

1.	Messenger RNA (mRNA)
2.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
3.	Collagen
4.	Transforming Growth Factor beta (TGF-beta)
5.	Transforming Growth Factor beta2
6.	Tissue Inhibitor of Metalloproteinase-1
7.	Fibronectins (Fibronectin)
8.	Transforming Growth Factor beta3 (TGF beta 3)
9.	Interleukin-10 (Interleukin 10)
10.	Collagen Type I (Type I Collagen)

Related Therapies and Procedures

1.	Transplants (Transplant)
2.	Homologous Transplantation (Allograft)
3.	Drug Therapy (Chemotherapy)
4.	Immunomodulation
5.	Oral Administration